Effect of spironolactone combined with angiotensin‑converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease

Wang,Weisong; Li,Lihua; Zhou,Zhonghai; Gao,Junjie; Sun,Yinghao

doi:10.3892/etm.2013.1335

Effect of spironolactone combined with angiotensin‑converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease

Authors:
- Weisong Wang
- Lihua Li
- Zhonghai Zhou
- Junjie Gao
- Yinghao Sun
View Affiliations

Affiliations: Department of Nephrology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
Published online on: October 9, 2013 https://doi.org/10.3892/etm.2013.1335
Pages: 1527-1531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to observe the effects of spironolactone on urine protein level and kidney function in patients with chronic glomerular disease receiving angiotensin‑converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs). A total of 221 patients with chronic glomerular disease were divided into spironolactone and control groups. The spironolactone group was treated with spironolactone at a dose of 20 mg/day, in addition to the original treatment regime and doses of ACEIs and/or ARBs. The control group continuously received the original doses of ACEIs and/or ARBs alone. Twenty‑four‑hour urine protein levels, serum creatinine and potassium, plasma aldosterone (ALD) and blood pressure were monitored at 0, 4, 8, 12 and 16 weeks. The estimated glomerular filtration rates (eGFRs) were calculated based on the obtained serum creatinine results. Following treatment, the urine protein level in the spironolactone group was notably decreased compared with that prior to the treatment, whereas the urine protein level in the control group did not show a significant difference. No significant differences were observed with regard to the renal function, eGFR, serum potassium, plasma ALD and blood pressure in either group prior to and following treatment. In conclusion, spironolactone administration, when co-administered with ACEIs and/or ARBs, markedly decreases the urine protein levels in patients with chronic glomerular disease. The protective effect of spironolactone on renal function remains to be demonstrated.

View Figures

View References

1	Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 37:677–688. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hostetter TH, Rosenberg ME, Ibrahim HN and Juknevicius I: Aldosterone in progressive renal disease. Semin Nephrol. 21:573–579. 2001. View Article : Google Scholar : PubMed/NCBI
3	Nagase M and Fujita T: Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 12:233–242. 2008. View Article : Google Scholar
4	Cravedi P, Brusegan V, Ruggenenti P, Campbell R and Remuzzi G: Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work? Pharmaceuticals. 3:1–9. 2010. View Article : Google Scholar
5	Sato A and Saruta T: Aldosterone escape during angiotensin converting patients enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 29:13–21. 2001. View Article : Google Scholar
6	Sato A, Hayashi K, Naruse M and Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 41:64–68. 2003. View Article : Google Scholar : PubMed/NCBI
7	Sato A, Saruta T and Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 29:211–216. 2006. View Article : Google Scholar : PubMed/NCBI
8	Tang WH, Vagelos RH, Yee YG, et al: Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 39:70–78. 2002. View Article : Google Scholar : PubMed/NCBI
9	Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68:2829–2836. 2005. View Article : Google Scholar : PubMed/NCBI
10	Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70:536–542. 2006.PubMed/NCBI
11	Rachmani R, Slavachevsky I, Amit M, et al: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med. 21:471–475. 2004. View Article : Google Scholar
12	Rossing K, Schjoedt KJ, Smidt UM, Boomsma F and Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 28:2106–2012. 2005. View Article : Google Scholar
13	Praga M, Gutiérrez E, González E, Morales E and Hernández E: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 14:1578–1583. 2003. View Article : Google Scholar : PubMed/NCBI
14	Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiprotennuric in IgA nephropathy. Am J Kidney Dis. 38:18–25. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:851–860. 2001. View Article : Google Scholar
16	Nakao N, Yoshimura A, Morita H, Takada M, Kayano T and Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotension-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 361:117–124. 2003. View Article : Google Scholar
17	Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 2:47–54. 1996. View Article : Google Scholar : PubMed/NCBI
18	Bomback AS, Kshirsagar AV, Amamoo MA and Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis. 51:199–211. 2008. View Article : Google Scholar : PubMed/NCBI
19	de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65:2309–2320. 2004.PubMed/NCBI
20	Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 60:1131–1140. 2001. View Article : Google Scholar : PubMed/NCBI
21	Ruggenenti P, Perna A and Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63:2254–2261. 2003. View Article : Google Scholar : PubMed/NCBI
22	Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K and Hebert LA: Management of glomerular proteinuria: A commentary. J Am Soc Nephrol. 14:3217–3232. 2003. View Article : Google Scholar : PubMed/NCBI
23	Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 45:281–287. 2005. View Article : Google Scholar : PubMed/NCBI
24	Cha DR, Kang YS, Han SY, et al: Role of Aldosterone in diabetic nephropathy. Nephrology (Carlton). 10(Suppl): S37–S39. 2005. View Article : Google Scholar : PubMed/NCBI
25	Han SY, Kim CH, Kim HS, et al: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 17:1362–1372. 2006. View Article : Google Scholar : PubMed/NCBI
26	Han KH, Kang YS, Han SY, et al: Spironolatone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 70:111–120. 2006. View Article : Google Scholar : PubMed/NCBI
27	Bianchi S, Bigazzi R and Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70:2116–2123. 2006.PubMed/NCBI
28	Sato A, Hayashi K and Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 18:44–49. 2005. View Article : Google Scholar : PubMed/NCBI
29	Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 351:543–551. 2004. View Article : Google Scholar : PubMed/NCBI
30	Struthers A, Krum H and Williams GH: A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 31:153–158. 2008. View Article : Google Scholar : PubMed/NCBI